AI Biotech's Revenue Surge
MindWalk Holdings' AI pivot drives 46% revenue surge and first recurring platform deals.
Anonymous
MindWalk Holdings Corp. (Nasdaq: HYFT), a small-cap AI biotech focused on drug discovery, reported a 46% revenue jump for the fiscal year ending April 30, 2026 — growing from C$2.7 million to C$4.1 million in its fourth quarter alone, according to Financial Post. The company also signed its first two recurring enterprise contracts for its LensAI™ platform, marking the first time in its history it has locked in steady, subscription-style revenue.
The results show a company in the middle of a real business shift. Gross margin hit roughly 60.6% in Q4, and the annual net loss narrowed by more than half, according to National Post. MindWalk also regained Nasdaq listing compliance — without a reverse stock split or dilutive new share issuance.
From One-Off Projects to Recurring Software Revenue
The biggest story in MindWalk's results is not the revenue number — it's the type of revenue. The company signed two contracted, recurring enterprise LensAI™ agreements during the year, according to Northern News. Before this, all of MindWalk's income came from one-off project work. Recurring contracts are more predictable and more valuable to investors.
LensAI™ is MindWalk's AI platform for drug discovery. It helps pharmaceutical companies find and develop drug candidates faster. Locking in enterprise clients on long-term deals means the company now has a base of revenue it can count on each year — a key milestone for any software business trying to prove it can scale, according to Shoreline Beacon.
Four Straight Quarters of Year-Over-Year Revenue Growth
MindWalk's Q4 revenue growth was not a one-quarter spike. The company posted year-over-year revenue gains in each of the last four quarters, according to Financial Post. That kind of streak matters because it suggests a trend, not a fluke. Full-year gross margin came in at roughly 59%, up from earlier periods.
The net loss for the full fiscal year narrowed by more than half compared to the prior year, according to County Market. That means MindWalk is growing revenue while also cutting losses — a combination that signals improving business health for an early-stage AI company.
Nasdaq Compliance Regained Without Diluting Shareholders
MindWalk also resolved a serious regulatory problem during the year. The company regained compliance with Nasdaq listing rules, according to Leader Post. Crucially, it did this without a reverse stock split — which would have reduced the number of shares outstanding — and without issuing new shares to raise cash, both of which tend to hurt existing shareholders.
Regaining compliance the clean way is a meaningful signal. It means the company stabilized its stock and its finances through operating progress rather than financial engineering, according to Edmonton Sun.
What the Numbers Mean for MindWalk's Drug Discovery Bet
MindWalk calls itself a "Bio-Native AI" company — meaning its AI tools are built specifically for biology and drug development, not adapted from general-purpose models. The LensAI™ platform sits at the center of that strategy. The first recurring contracts show that pharmaceutical clients are willing to pay for the platform on an ongoing basis, not just for single projects, according to Seaforth Huron Expositor.
The drug discovery AI market is competitive, with large players spending heavily in the space. MindWalk's results for fiscal 2026 are still small in absolute dollar terms. But the combination of 46% revenue growth, expanding margins, a narrowing loss, and the first recurring contracts gives the company a cleaner story to tell investors heading into its next fiscal year.
Sentiment
NeutralNEGATIVENEUTRALPOSITIVE
Publishers
8
Articles
8
Reach
8
A
AnonymousAuthor